Mr. Nickl took on his role on June 1, following the resignation of Johannes Dietsch. U.S. regulators approved the $63 billion transaction on May 29. Nickl has to make sure that Bayer squeezes cash from anywhere they can,” said Mr. Redenius. Bringing down the company’s debt is another task for Mr. Nickl. Still, those concerns should not be overblown as Bayers should not find it difficult to sell its bonds, said Mr. Redenius.

Source: Wall Street Journal June 04, 2018 18:00 UTC